Health Care/Hospital
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
* BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. * JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing anext-generation therapeutic. * BioDlink provided end-to-end devel...
2025-05-08 20:30
4292
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
* Penetrium™ Achieves Historic Breakthrough * Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy * Presented at AACR 2025, Chicago CHICAGO, May 7, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combinati...
2025-05-08 09:03
2447
Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting
CHICAGO, May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Associat...
2025-05-07 21:30
1951
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics ...
2025-05-07 21:00
2439
Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture
– Conducted under U.S. FDA-cleared IND – Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part of its ...
2025-05-07 21:00
2513
Zepp Health Corporation to Report First Quarter 2025 Financial Results on May 19, 2025
Earnings Call Scheduled for 9:00 p.m. ET on May 19, 2025 MILPITAS, Calif., May 7, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its first quarter 2025 unaud...
2025-05-07 20:00
4232
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
* Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo * Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in...
2025-05-07 20:00
2220
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bis...
2025-05-07 08:00
1963
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inMexico for the commercialization of clobetasol propionate ophthalmic...
2025-05-07 06:30
1900
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, aNorthern Ireland-based research driven drug discovery company, for exclusive rights to the commercializ...
2025-05-06 21:00
2100
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...
2025-05-06 20:00
2473
Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform,...
2025-05-06 10:01
1966
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagoni...
2025-05-06 07:00
1986
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...
2025-05-04 14:48
3064
A Masterpiece in Metal and Light: Groundbreaking Ceremony for the CMU Museum of Fine Arts Marks a Milestone in Taiwan's Architectural History
Frank Gehry's Sole Major Project in East Asia Begins to Rise in Taichung TAICHUNG, May 3, 2025 /PRNewswire/ -- On May 3, 2025, beneath the ever-shifting skies of Taichung's Shui-Nan campus, China Medical University (CMU) broke ground on what promises to be a transformative landmark for Taiwan—th...
2025-05-03 20:00
4909
Unilever's CLEAR Launches Scientific Anti-Dandruff Series: Lab-Proven Tech Targets Oil, Flakes, and Sensitivity
SHANGHAI, May 3, 2025 /PRNewswire/ -- On April 17, 2025, CLEAR, Unilever's premium professional anti-dandruff brand, officially launched its first SCALPCEUTICALS PRO RANGE globally at TANK Shanghai. This series embodies the brand's 50 years of scientific research and unites the efforts of five gl...
2025-05-03 15:12
3751
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking ...
2025-05-02 19:30
2806
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration
company, Aroa Biosurgery, is pleased to announce a milestone in clinical
evidence.
2025-05-02 10:42
2929
FaceHeart Received Another FDA Clearance for its Contactless Video-Based Vital Sign Measurement of Respiratory Rate
* Developed by FaceHeart, FH Vitals SDK-RR has obtained FDA Clearance. This is the second 510(k) class II SaMD (Software as a Medical Device) FaceHeart received from the FDA. * FaceHeart Vitals™ is a video-based, contactless vital sign measurement SDK that can be integrated into devices such ...
2025-05-01 23:06
2700
No-Drama Modern Parenting: GROWNSY Shares 10 Must-Have Upgrades for Modern Moms This Mother's Day
Because modern moms don't need clichés, they need real solutions.
NEW YORK, May 1, 2025 /PRNewswire/ -- Today's parents are more informed, more
intentional and frankly, more exhausted than ever before. And while the world
keeps telling them to "enjoy every moment,"GROWNSY
2025-05-01 21:00
2125
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
